Payment overview · 2025
General Payments
$74.31
4 reported records · 3 companies
Healthcare provider profile · identity verified
Joshua Krumenacker, MD, PHD
Allopathic & Osteopathic Physicians|Family Medicine · WELLINGTON, FL · NPI 1841589280
Verified facts
What the public records show
CMS Open Payments records show Joshua Krumenacker, MD, PHD received $74.31 in general payments during 2025 across 4 reported records.
ABBVIE INC. accounted for 46.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.38 | 46.3% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $24.52 | 33.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.41 | 20.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $74.31 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $24.52 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $24.52 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.31 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 550 | 155 |
| Atorvastatin Calcium | Atorvastatin Calcium | 523 | 163 |
| Levothyroxine Sodium | Levothyroxine Sodium | 429 | 100 |
| Lisinopril | Lisinopril | 374 | 99 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 361 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 304 | 77 |
| Metformin Hcl | Metformin Hcl | 273 | 98 |
| Metoprolol Succinate | Metoprolol Succinate | 268 | 73 |
| Losartan Potassium | Losartan Potassium | 246 | 72 |
| Gabapentin | Gabapentin | 241 | 75 |
| Omeprazole | Omeprazole | 241 | 77 |
| Carvedilol | Carvedilol | 191 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 185 | 52 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 167 | 42 |
| Furosemide | Furosemide | 163 | 57 |
| Simvastatin | Simvastatin | 144 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 143 | 53 |
| Eliquis | Apixaban | 142 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 137 | 42 |
| Meloxicam | Meloxicam | 130 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 31 |
| Farxiga | Dapagliflozin Propanediol | 128 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 124 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 37 |
| Allopurinol | Allopurinol | 109 | 29 |
| Trazodone Hcl | Trazodone Hcl | 108 | 34 |
| Potassium Chloride | Potassium Chloride | 105 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 40 |
| Tramadol Hcl | Tramadol Hcl | 99 | 26 |
| Montelukast Sodium | Montelukast Sodium | 95 | 28 |
| Famotidine | Famotidine | 94 | 29 |
| Ozempic | Semaglutide | 89 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 20 |
| Sertraline Hcl | Sertraline Hcl | 80 | 24 |
| Alendronate Sodium | Alendronate Sodium | 79 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 17 |
| Metformin Hcl Er | Metformin Hcl | 74 | 19 |
| Valsartan | Valsartan | 73 | 20 |
| Buspirone Hcl | Buspirone Hcl | 69 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 16 |
| Irbesartan | Irbesartan | 68 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 21 |
| Glipizide | Glipizide | 65 | 20 |
| Mounjaro | Tirzepatide | 65 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 21 |
| Celecoxib | Celecoxib | 63 | 19 |
| Prednisone | Prednisone | 60 | 44 |
| Spironolactone | Spironolactone | 57 | 18 |
| Alprazolam | Alprazolam | 53 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 51 | 13 |
| Synthroid | Levothyroxine Sodium | 51 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 44 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 43 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Ezetimibe | Ezetimibe | 42 | 15 |
| Glimepiride | Glimepiride | 41 | 14 |
| Lorazepam | Lorazepam | 41 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 40 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | 11 |
| Doxepin Hcl | Doxepin Hcl | 38 | 11 |
| Jardiance | Empagliflozin | 37 | suppressed |
| Pregabalin | Pregabalin | 36 | suppressed |
| Linzess | Linaclotide | 35 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 35 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 31 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Azithromycin | Azithromycin | 28 | 20 |
| Eszopiclone | Eszopiclone | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Ranolazine Er | Ranolazine | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 14 |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | 11 |
| Indomethacin | Indomethacin | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Dexilant | Dexlansoprazole | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Lexapro | Escitalopram Oxalate | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Captopril | Captopril | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $74.31 · 4 records | ABBVIE INC. | APTIMA, JARDIANCE, QULIPTA, THINPREP 2000 PROCESSOR, UBRELVY, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error